Utilization of orphan drugs in the U.S. by usage type 2014

This statistic depicts the percentage of select orphan drugs that were utilized in select way in the U.S. during 2014, by utilization type. According to the data, 98.5 percent of Gralise usage was for off-label use. Orphan drugs, once approved, are sometimes expanded to cover several other indications. In fact, many orphan drugs are utilized more often in non-orphan areas than in the original aimed orphan area.

Percentage of annual utilization among select orphan drugs in the U.S. in 2014, by usage type

Orphan useNon-orphan useOff-label use
Xiaflex98.101.9
Kalydeco97.902.1
Ampyra97.202.8
Caprelsa96.703.3
Cayston96.303.7
Xalkori95.204.8
Vpriv95.104.9
Iclusig**9505
Velcade94.705.3
Soliris94.205.8
Jakafi92.207.8
Promacta89.55.54.9
Zelboraf88.6011.4
Lumizyme***88.1011.9
Mozobil87.5012.5
Berinert86.4013.6
Nplate84.8015.2
Cinryze83.1016.9
Tyvaso82.9017.1
Kalbitor81.8018.2
Ferriprox76.3023.7
Firazyr65.6034.4
Makena62.9037.1
Adcirca60.2039.8
Onfi54.5045.5
Zirgan52.2047.8
Banzel44.7055.3
Sabril43.822.933.3
Xenazine39.1060.9
Cuvposa34.1065.9
Votrient32.4607.6
Gamunex23.752.923.4
Sensipar19.475.94.7
Gleevec19.367.613.1
Rituxan12.864.922.3
Afinitor10.770.418.9
Avastin10.216.373.5
Herceptin2.496.41.3
Humira2.490.96.7
Coartem2.2097.8
Remicade1.6962.4
Gralise1.5098.5
Horizant*128.470.5
Colcrys0.362.836.9
Viread090.99.1
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

October 2016

Region

United States

Survey time period

2014

Supplementary notes

* The cumulative price change is based on changes in the unit price for NDC #00173-0806-01 & #53451-0101-01.
** As Iclusig was not approved by the FDA until December, 2012 it was included in the study; however, its pricing and utilization data were from 2013 to 2014 only.
*** Includes patients prescribed Myozyme.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.